Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MBS2320 in Healthy Volunteers and RA Patients
NCT02480946Phase 1Completed
- Sponsor
- Modern Biosciences
- Start
- Jul 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Leramistat in rheumatoid arthritis (RA) (4 arms), sponsored by Modern Biosciences. Primary endpoint: Incidence of all grade adverse events and dose limiting toxicities at 7 days. Started Jul 2015; status: completed.
02
Drugs
Leramistat
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02480946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02480946.